Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Expands By 7.7%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 119,200 shares, a growth of 7.7% from the November 30th total of 110,700 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 33,100 shares, the short-interest ratio is currently 3.6 days.

Cyclo Therapeutics Price Performance

Shares of CYTH remained flat at $0.59 during mid-day trading on Thursday. 1,611 shares of the stock traded hands, compared to its average volume of 65,934. The company has a market cap of $16.97 million, a price-to-earnings ratio of -0.66 and a beta of -0.46. Cyclo Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.12. The company has a 50-day moving average price of $0.67 and a 200-day moving average price of $0.87.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.